XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Data
 12 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services.
Medical
Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Pharmaceutical Systems.
Life Sciences
Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics;
blood banks; healthcare workers; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences.
Interventional
Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care.
Additional Segment Information
Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented.
Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment.
The tables below reflect the Company’s revenues and operating income from continuing operations. Revenues and operating income from the former Diabetes Care business prior to its spin-off on April 1, 2022 are included in (Loss) Income from Discontinued Operations, Net of Tax. See Note 2 for further information.
Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars)202320222021
United StatesInternationalTotalUnited StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$2,519 $1,774 $4,293 $2,483 $1,825 $4,308 $2,253 $1,848 $4,101 
Medication Management Solutions2,303 677 2,980 1,935 598 2,533 1,863 570 2,432 
Pharmaceutical Systems666 1,563 2,229 533 1,468 2,001 428 1,400 1,828 
Total segment revenues$5,488 $4,014 $9,502 $4,950 $3,891 $8,841 $4,544 $3,817 $8,361 
Life Sciences
Integrated Diagnostic Solutions$1,774 $1,850 $3,624 $2,190 $1,995 $4,185 $2,477 $2,748 $5,225 
Biosciences603 906 1,509 542 838 1,379 503 802 1,305 
Total segment revenues$2,377 $2,756 $5,133 $2,732 $2,833 $5,564 $2,980 $3,550 $6,530 
Interventional
Surgery $1,159 $338 $1,497 $1,094 $306 $1,400 $1,023 $274 $1,296 
Peripheral Intervention1,016 849 1,865 960 799 1,759 931 780 1,711 
Urology and Critical Care1,073 301 1,374 986 319 1,305 894 338 1,232 
Total segment revenues$3,247 $1,489 $4,736 $3,040 $1,424 $4,464 $2,847 $1,392 $4,239 
Total Company revenues from continuing operations$11,113 $8,258 $19,372 $10,722 $8,148 $18,870 $10,371 $8,760 $19,131 
The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.
(Millions of dollars)202320222021
Income from Continuing Operations Before Income Taxes
Medical (a) (b) $1,967 $2,215 $1,985 
Life Sciences1,585 1,710 2,391 
Interventional 1,217 1,081 933 
Total Segment Operating Income
4,769 5,006 5,311 
Acquisition-related integration and restructuring expense(313)(173)(179)
Net interest expense(403)(382)(460)
Other unallocated items (c)(2,391)(2,668)(2,981)
Total Income from Continuing Operations Before Income Taxes$1,662 $1,783 $1,692 
Capital Expenditures
Medical$563 $602 $740 
Life Sciences139 213 297 
Interventional138 130 125 
Corporate and All Other35 28 32 
Total Capital Expenditures$874 $973 $1,194 
Depreciation and Amortization
Medical$1,199 $1,144 $1,097 
Life Sciences277 283 352 
Interventional799 789 769 
Corporate and All Other13 13 12 
Total Depreciation and Amortization$2,288 $2,229 $2,230 
(a)The amounts in 2023, 2022 and 2021 include charges of $653 million, $72 million and $56 million, respectively, recorded to Cost of products sold, to adjust estimated future product remediation costs.
(b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit.
(c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. The amount in 2021 includes a pre-tax charge recorded to Other operating (income) expense, net, related to certain product liability matters of $361 million, as further discussed in Note 6.
Geographic Information
The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada.
Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.
The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars)202320222021
Revenues
United States$11,113 $10,722 $10,371 
EMEA4,244 4,043 4,548 
Greater Asia2,913 3,047 3,069 
Other1,102 1,058 1,142 
$19,372 $18,870 $19,131 
Long-Lived Assets
United States$35,732 $36,617 $35,896 
EMEA5,317 5,126 5,778 
Greater Asia1,521 1,528 1,607 
Other1,116 1,079 860 
Corporate418 442 465 
$44,104 $44,792 $44,606